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Nitric oxideAbstract Background: Renal ischemia–reperfusion (RIR) is an important etiopathological mech-
anism of acute renal failure (ARF). Erythropoietin (EPO) has been candidate as a nephroprotectant
agent. However, its nephroprotective effect when it is accompanied with estrogen has not been stud-
ied in female.
Methods: Fifty-six female rats were divided into seven groups. Each formed of 8 rats. Group I:
control group. Group II: Female rats exposed to RIR (named RIR group).Group III: Female rats
exposed to RIR and pretreated with EPO (named RIR + EPO group). Group IV: ovariectomized
rats exposed to RIR (named OVR + RIR group). Group V: ovariectomized rats received estrogen
(E) then exposed to RIR (named OVR + RIR + E group). Group VI: ovariectomized rats received
EPO before RIR (named OVR + RIR + EPO group). Group VII: ovariectomized rats received E
then received EPO before RIR (named OVR +RIR + E + EPO group).Serum creatinine, blood
urea nitrogen (BUN) and renal blood flow (RBF) were measured. Tumor necrosis factor-a
(TNF-a), Myeloperoxidase activity (MPO), nitric oxide (NO), endothelin-1(ET-1) and EPO levels
were assessed in the renal tissue. Histopathology was assessed to detect renal damage score.
Results: RIR significantly increased the serum levels of creatinine and BUN with decrease in RBF.
In addition it significantly increased TNF-a, MPO and endothelin-1 levels with decrease in NO and
EPO levels in renal tissue. However, these parameters significantly reversed by EPO except RBF.
Combination of E and EPO leads to significant decrease in the protective effect of EPO.
Conclusion: It seems that EPO could protect the kidney against RIR, while this protective effect
was decreased when E was supplemented.
 2015 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).F, renal
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ARF caused by RIR is an important clinical problem. Even
though great progress has been made in patient care, there is
still high morbidity and mortality associated with ARF.1RIR
injury occurs in various clinical settings including severe
hypotension and subsequent resuscitation, shock, sepsis, renal
transplantation and aorto-vascular Surgery.2
There is growing evidence which indicates that sex differ-
ences exist in kidney response to renal ischemic injury with
increased male susceptibility to acute and chronic renal injury
than that of female.3Detailed cellular and molecular mecha-
nisms of these differences are still unknown, and they involve
genomic and non-genomic effects of sex hormones, particu-
larly estrogen.4
Endothelial dysfunction is an important component of ini-
tiating and continuing renal tubular epithelial injury and con-
tributes to the pathogenesis of ischemic ARF.5Endothelial
injury may aggravate the inflammatory response through loss
of normal nitric oxide (NO) production due to inhibition of
endothelial nitric oxide synthase (eNOS). NO reduces
leukocyte-induced injury by blocking leukocyte sequestration
and activation. However, RIR also increases inducible nitric
oxide synthase (iNOS), which potentiates injury. Also, the high
output production by iNOS might suppress eNOS. This imbal-
ance between the two NOS may be an important component of
RIR injury.6
Inflammation contributes to the pathogenesis of RIR injury
in a variety of contexts. Inflammation can result in reduction
in local blood flow to the outer medulla, with adverse conse-
quences on tubule function and viability. There has been some
controversy about the relative importance of various sub-
groups of leukocytes as neutrophils to RIR injury.7
There is a controversy on the effect of E on renal function
of ovariectomized rats. As some studies reported more deteri-
oration by administration of E, others reported an improve-
ment of renal function.
EPO is an essential growth factor of hemopoietic progeni-
tor cells, but its extrahemopoietic effects imply additional ther-
apeutic possibilities. Indeed, a wealth of experimental data is
being generated with respect to the protective effect of EPO
against the ischemic myocardium, liver, and renal injury.8In
addition; there exist sex differences in endogenous erythropoi-
etin. The concentration of erythropoietin is higher in males
than in females.9
Experimental evidence suggests that E inhibits production
of EPO in female rats, when rats have exposed to various
intensities of ischemia, which is confirmed by production of
lower amounts of EPO in normal females than in normal
males.10 Accordingly, the protective roles of EPO against
RIR may change when E is accompanied by EPO. Therefore,
this study was designed to find the protective role of EPO in
RIR when it is accompanied by E.
2. Methods
2.1. Animals
Experiments were performed on 56 sexuallymature female rats
(weighing 200–250 g). Experimental Animals were approved
by the Ethical Committee of the Faculty of Medicine, BenhaUniversity, Egypt. Rats were fed with a standard laboratory
diet and water ad libitum. Animals were left to acclimatize
to the environment for two weeks prior to inclusion in the
experiment.
The rats were divided into 7 different groups (n= 8).
Group I: Control sham-operated female rats (rats were sub-
jected to midline laparotomy and dissection of renal pedicles
without any renal ischemia) only receive Sesame oil by sc route
for three weeks (control group).
Group II: female rats received Sesame oil by sc route for
three weeks then exposed to bilateral RIR; ischemia was pro-
duced for 50 min, followed by 2 hs reperfusion (RIR group).11
Group III: female rats received Sesame oil by sc rout for
three weeks then treated with EPO 5000 U/kg single dose IP,
20 min before ischemia (named RIR + EPO group).12
Group IV: female rats exposed to bilateral ovariectomy
then after one week they received Sesame oil by sc rout for
three weeks then exposed to RIR (named OVR + RIR).13
Group V: female rats exposed to bilateral ovariectomy
then after one week they received estrogen supplementation
(25 lg/kg/day; SC) for three weeks then exposed to RIR
(OVR+ E + RIR).14
Group VI: female rats exposed to bilateral ovariectomy
then after one week they received Sesame oil by sc rout for
three weeks then treated with EPO 5000 U/kg single dose IP,
20 min before ischemia (named OVR + RIR+ EPO group).
Group VII: Ovariectomized rats received estrogen for
3 weeks, and then received EPO 20 min before ischemia
(named OVR + RIR+ E+ EPO group).
2.2. Chemicals
Estrogen in the form of Folone ampoules, each 1 ml ampoule
contains 5 mg estradiol benzoate in oily solution, was pur-
chased from Misr Co., for Pharm. ind. S.A.E. (Cairo, Egypt).
Sesame oil was purchased from Indian Co. (Cairo, Egypt).
Thiopental sodium was purchased from Eipico Co. (Cairo,
Egypt) and Erypro Safe (5000 i.u) (Erythropoietin) from Bio-
con (India) Ltd., from Pharma Co.
2.3. Preparation of E solution
Eused in this studywas a liquid in Folone ampoules (5 mg estra-
diol benzoate/ml) in oily solution. The injection solution was
prepared by dissolving 1 ml of estradiol benzoate in 36 ml
ethanol-sesame oil to give a concentration of 25 lgE in 0.2 ml
final solution. All rats in all groups except that treated with E
only received an oily solution as a vehicle (0.2 ml/kg/day SC).
2.4. RIR injury animal model
Rats were anesthetized by intraperitoneal injection with
thiopental sodium (30 mg/kg). A Midline abdominal incision
was made and both kidneys were exposed. Renal ischemia was
induced by non-traumatic vascular clamps over the pedicles
(arteries and veins) of the two kidneys for 50 min. Following
the occlusion, the presence of ischemia was visually confirmed
by observing blanching of the kidneys. During the period of
ischemia, the edges of the abdominal incision were approxi-
mated to each other and covered by a cotton pad soaked with
warm isotonic saline (37 C) to prevent undue loss of body
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blood flow then the kidneys were observed for an additional
1 min to see the color change indicative of blood reflow.152 hs
after reperfusion RBF was measured then blood samples were
obtained via heart puncture. Serum samples were removed
and stored at 20 C until measurement. Right kidney was
removed for preparation of renal tissue homogenate and the left
kidney was removed and fixed in 10% formalin solution for
pathological assessments. In sham-operated group, the same
surgical procedures were done but without applying the clamps.
2.5. Ovariectomized rat model
The rat was anesthetized by thiopental sodium (30 mg/kg).
The anesthetized rat was placed on the operating board in dor-
sal recumbency with its tail directed toward the surgeon. The
ventral aspect of the lumbar region was shaved, and then
cleaned with 75% ethanol, followed by thorough scrubbing
with 10% povidone iodine (Betadine). 1 cm long longitudinal
ventral midline incision was made above the symphysis pubis
by a scalpel blade; the skin edges were laterally retracted,
and the abdominal muscle layer and the peritoneum were
incised. Both fallopian tubes were exposed and ligated; the
ovary can usually be seen embedded in a pad of fat in the
abdomen; then the ovaries were removed by cutting them with
scissors, taking care not to rupture the ovarian capsules. The
remaining tissues were replaced into the peritoneal cavity.
The incision was then closed using a sterile 2/0 suture. The
removed tissue was ensured to be the ovaries by histological
sections. The rats were returned to their cages and left for
about four weeks till RIR.16
2.6. Mortality rate
Four rats died during the surgical procedures.
2.7. Assessment of renal function
Serum creatinine was assessed using the Jaffe´ picric acid proce-
dure17 with Sigma kit 555-A# (Sigma–Aldrich Chemical Co.).
BUN was assessed by enzymatic method18 (modified Berthelot
reaction) (dp international; Tuscaloosa: USA).
2.8. Measurement of renal blood flow by Doppler flow meter
The left kidney was exposed through a flank incision, and its
artery was cleared of connective tissue so that an electromag-
netic flowmeter probe (Carolina Medical Electronic, King,
NC, USA) could be fitted.19
2.9. Measurement of nitric oxide (NO)
Kidney tissue was homogenized in 5–10 ml cold buffer (50 mM
potassium phosphate, pH 7.5. 1 mM EDTA) per gram tissue.
Homogenate was centrifuged and supernatant was removed
for assay. NO level was determined indirectly as its metabolic
products (nitrate + nitrite ions) spectrophotometrically using
Bio Assay Systems’ Quanti Chrom TM Nitric Oxide Assay
Kit to measure NO production following reduction of nitrate
to nitrite using improved Griess method.202.10. Renal ET-1 assay
ET-1 was extracted from the kidney. The radioimmunoassay
for ET-1 was performed as described previously21
2.11. Estimation of renal tissue TNF-a
Estimation of renal tissue TNF-a was done by commercial
sandwich Elisa kits for rats according to manufacturer’s
instructions (Sigma–Aldrich Co., St Louis, MO, USA). The
concentrations of TNF-a in kidney tissues were expressed as
pg/mg protein.22
2.12. Estimation of neutrophil accumulation
MPO activity was measured as an index of neutrophil accumu-
lation. Tissue MPO activity was assessed using a commercial
assay kit (Hycult Biotech Inc., Burlington, CA). The MPO
activity was expressed as U/g of tissue.22
2.13. Determination of renal EPO concentrations
Renal erythropoietin levels were determined by EPO ELISA
kit and were expressed as pg/ml as described previously.23
2.14. Histopathological procedures
The left kidney was fixed in 10% formalin solution and embed-
ded in paraffin. The tissue slices were stained by hematoxylin
and eosin (H & E) to examine the tissue damage based on
the presence of tubular atrophy, hyaline cast, ischemic necro-
sis, vacuolization, and debris. According to the damage inten-
sity, the samples were scored as 1–4 and 0 means normal (no
tissue damage): 1. means low damage (up to 25% of tissue
damage), 2. means mild damage (between 26% and 50% of tis-
sue damage), 3. means moderate damage (between 51% and
75% of tissue damage) and 4. means severe damage (more than
75% of tissue damage).24
2.15. Statistical analysis
All the data are presented as mean ± standard deviation (SD).
Evaluation of differences between groups was performed using
one-way analysis of variance (ANOVA) with SPSS 19.0 soft-
ware. A P-value of less than 0.05 was considered statistically
significant.
3. Results
3.1. Effect of erythropoietin and estrogen on serum creatinine,
BUN and renal blood flow (RBF) in ovariectomized rats
exposed to RIR
Table 1 shows that serum creatinine and BUN were signifi-
cantly elevated (p < 0.001) and RBF was significantly
decreased (p< 0.001) in RIR group (group II) and OVR +
RIR group (group IV) compared to control group. There
was significant decrease (p < 0.001) in serum creatinine and
BUN with non-significant increase in RBF in RIR + EPO
group (group III) when compared with RIR group (group
Table 1 Comparison between mean ± SD of serum creatinine (mg/dl), blood urea nitrogen (BUN) (mg/dl) and RBF cm/s in group
(I): control group, group II: (RIR group), group III: (EPO + RIR group), group IV: (OVR + RIR group), group V: (OVR + RIR
+ E group), group VI: (OVR + RIR + EPO group) and group (VII): (OVR + RIR + E + EPO group).
Parameter groups Serum creatinine (mg/dl) Blood urea nitrogen (BUN) (mg/dl) RBF cm/s
Group (I) n = 8 0.5 ± 0.06 37.3 ± 0.39 9.5 ± 0.17
Group (II) n = 7 3.7 + 0.22a 67.7 ± 1.4a 4.5 ± 0.13a
Group (III) n = 8 1.8 ± 0.32b 57.4 ± 2.2b 4.6 ± 0.27b
Group (IV) n= 6 5.5 ± 0.15ab 88.6 ± 1.3ab 3.1 ± 0.12ab
Group (V) n= 7 3.5 + 0.14d 61.2 ± 1.3bd 8.3 ± 0.32d
Group (VI) n= 8 1.05 ± 0.16bcde 43.9 ± 0.75bde 4.09 + 0.25bde*
Group (VII) n= 8 2.6 ± 0.16def 52.9 + 0.96def 6.6 ± 0.36def
a Statistically significant compared to the corresponding value in group (I) (p < 0.001).
b Statistically significant compared to the corresponding value in group (II) (p < 0.001).
c Statistically significant compared to the corresponding value in group (III) (p< 0.001).
d Statistically significant compared to the corresponding value in group (IV) (p< 0.001).
e Statistically significant compared to the corresponding value in group (V) (p< 0.001).
f Statistically significant compared to the corresponding value in group (VI) (p< 0.001).
* Statistically significant compared to the corresponding value in group (III) (p< 0.005).
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tinine and BUN and significant decrease (p < 0.001) in RBF
in OVR + RIR group (group IV) when compared with RIR
group (group II). Administration of E to ovariectomized rats
exposed to RIR as in group V leads to significant decrease
(p < 0.001) in serum creatinine and BUN and significant
increase (p < 0.001) in RBF when compared to OVR
+ RIR group (group IV). Administration of EPO to ovariec-
tomized rats exposed to RIR as in group VI leads to significant
decrease (p < 0.001) in serum creatinine and BUN and signif-
icant increase (p < 0.001) in RBF when compared to OVR
+ RIR group (group IV), and leads to significant decrease
(p < 0.001) in serum creatinine and BUN and significant
decrease (p < 0.001) in RBF when compared to OVR
+ RIR + E group (group V). Administration of EPO and E
to ovariectomized rats exposed to RIR as in group VII leads
to significant decrease (p < 0.001) in serum creatinine and
BUN and significant increase (p < 0.001) in RBF when com-
pared to OVR + RIR (group IV) and leads to significant
decrease (p < 0.001) in serum creatinine and BUN and signif-
icant decrease (p< 0.001) in RBF when compared to OVR
+ RIR + E group (group V). In addition it leads to signifi-
cant increase (p< 0.001) in serum creatinine and BUN and
significant increase (p < 0.001) in RBF when compared to
OVR + RIR + EPO group (group VI); this indicates that
administration of both E and EPO leads to significant decrease
in the protective effect of erythropoietin on urea and creati-
nine. Also there was significant decrease (p < 0.001) in serum
creatinine and BUN with significant increase (p < 0.005) in
RBF in OVR + RIR + EPO group (group VI) when com-
pared with RIR + EPO group (group III). Also effect of
EPO and E on RBF in ovariectomized rats exposed to RIR
is demonstrated in Fig. 1(A–G).
3.2. Effect of erythropoietin and estrogen on NO (nmol/l), ET-1
(ng/g) and erythropoietin (pg/ml) levels in renal tissue of
ovariectomized rats exposed to RIR
Table 2 shows that RIR as in group II caused significant
decrease (p < 0.001) in NO and erythropoietin levels with sig-
nificant increase (p< 0.001) in ET-1 levels in renal tissue whencompared with the control group. There was significant
increase (p< 0.001) in NO, ET-1 and Erythropoietin levels
in renal tissue in RIR + EPO group (group III) when com-
pared with RIR group (group II). RIR in ovariectomized rats
leads to significant decrease (p < 0.001) in NO and erythropoi-
etin levels with significant increase (p< 0.001) in ET-1 when
compared with RIR group (group II). Administration of estro-
gen to RIR in ovariectomized rats as in E + OVR +RIR
group (group V) leads to significant increase (p< 0.001) in
NO and significant (p< 0.001) decrease in ET-1 and erythro-
poietin levels when compared with OVR + RIR group (group
IV). Administration of EPO to RIR in ovariectomized rats as
in EPO + OVR + RIR group leads to significant increase in
NO (p< 0.001) and erythropoietin (p< 0.05) levels with
non-significant increase in ET-1 when compared with OVR
+ RIR group (group III). And when compared with OVR
+ RIR + E group (group IV) there is significant decrease
(p < 0.001) in NO and erythropoietin levels with significant
increase in ET-1. Combination of EPO and E to RIR in
ovariectomized rats as in OVR + RIR+ E + EPO group
leads to significant increase (p< 0.001) in NO and significant
decrease (p< 0.001) in ET-1 and erythropoietin (p< 0.05)
when compared with OVR + RIR group (group IV). While
there was significant decrease (p < 0.001) in NO and signifi-
cant increase (p < 0.001) in ET-1 when compared with group
V, there was significant increase (p < 0.001) in NO and signif-
icant decrease (p < 0.001) in ET-1 and erythropoietin levels
when compared with group VI.
3.3. Effect of EPO and E on TNF-a (pg/mg) and MPO (u/gm)
levels in renal tissue of ovariectomized rats exposed to RIR
Fig. 2(A and B) shows that RIR as in group II caused signif-
icant increase (p < 0.001) in TNF-a and MPO levels in renal
tissue when compared with the control group. Pretreatment
of RIR with EPO as in RIR + EPO group leads to significant
decrease (p< 0.001) in TNF-a and MPO when compared with
RIR group (group II). RIR in ovariectomized rats as in OVR
+ RIR (group IV) leads to significant increase in (p < 0.001)
TNF-a and MPO levels when compared with control group
and RIR group (group II). Pretreatment of ovariectomized
Figure 1 Effect of EPO and E on RBF in all groups. (A): A trace
showing RBF of control group. (B) A trace showing RBF of RIR
group. (C) A trace showing RBF of RIR + EPO group. (D) A
trace showing RBF of OVR + RIR group. (E) A trace showing
RBF of OVR + RIR + E group. (F) A trace showing RBF of
OVR+ RIR+ EPO group. (G) A trace showing RBF of OVR+
RIR+ E+ EPO group.
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leads to significant decrease (p < 0.001) of TNF-a and MPO
levels when compared with OVR+ RIR (group IV). Pretreat-
ment of ovariectomized rats with EPO prior to RIR as in
OVR + RIR + EPO (group VI) leads to significant decrease
(p< 0.001) of TNF-a and MPO levels when compared with
OVR + RIR (group IV) and OVR + RIR+ E (group V).
Pretreatment of ovariectomized rats with estrogen and EPO
prior to RIR as in OVR + RIR + E + EPO (group VII)
leads to significant decrease (p < 0.001) of TNF-a and MPO
levels when compared with OVR + RIR (group IV), OVR
+ RIR + E (group V) and non-significant decrease when
compared with OVR + RIR+ EPO (group VI).
3.4. Effect of EPO and E on damage score in renal tissue of
ovariectomized rats exposed to RIR as shown in Figs. 3 and 4
(A–G)
Histologically there was significant increase (p < 0.001) in
renal tissue damage in RIR (group II) when compared with
the control group. Pretreatment RIR with EPO leads to signif-
icant decrease (p< 0.001) in renal tissue damage when com-
pared with RIR group (group II). There was significant
decrease (p < 0.001) in group (V, VI and VII) when compared
with group IV. There was significant decrease in group VI
when compared with group II (p < 0.001), group III
(p< 0.001) and group V (p< 0.005). There was significant
decrease (p < 0.01) in renal tissue damage of group VII when
compared with group V and significant increase (p < 0.01)
when compared with group VI, indicating that combination
of estrogen and erythropoietin leads to decrease in the protec-
tive effect of erythropoietin on renal tissue damage.
4. Discussion
RIR has more destructive effects rather than ischemia alone.
The main mechanisms that underlying RIR induced damages
are microvascular dysfunctions, imbalance of vasoactive sub-
stances, oxidative stress, increased endothelial injury, and local
activation of inflammation. Different processes are started to
disturb structural and functional integrity of the kidney after
RIR.25
The main objective of this study was to determine the pro-
tective role of EPO against RIR induced renal injury and
studying its effect on vasoactive substances and local activa-
tion of inflammation when accompanied with estrogen.
In the present study, rats exposed to RIR showed a signif-
icant increase in the serum creatinine and BUN levels with sig-
nificant increase in renal damage score as shown by
histopathological examination when compared to the control
group. This is in accordance with the findings of many previ-
ous studies.26,27 RIR results in rapid loss of cytoskeletal integ-
rity, cell polarity and shedding of the proximal tubule brush
border. With severe injury, viable and nonviable cells are
desquamated leaving regions where the basement membrane
remains as the only barrier between the filtrate and the per-
itubular interstitium.28
Table 2 Comparison between mean ± SD NO (nmol/l), ET-1(ng/g) and EPO (Iu/l) levels in renal tissue of group (I): control group,
group II: (RIR group), group III: (RIR + EPO group), group IV: (OVR + RIR group), group V: (OVR + RIR + E group), group
VI: (OVR + RIR + EPO group) and group (VII): (OVR + RIR + E + EPO group).
Parameter groups NO level (nmol/l) ET-1 (ng/gm) Erythropoietin (pg/ml)
Group (I) n = 8 30.4 ± 1.4 0.53 ± 0.02 45.5 ± 1.8
Group (II) n = 7 16.7 ± 0.56a 1.5 ± 0.1a 27.6 ± 1.3a
Group (III) n = 8 21 + 1.3b 2.03 + 0.1b 40.5 + 1.8b
Group (IV) n= 6 12.2 ± 0.51ab 2.27 ± 0.18ab 33.3 ± 1.03b
Group (V) n= 7 29.2 ± 037d 0.83 ± 0.02d 18.1 ± 1.3d
Group (VI) n= 8 20.2 ± 0.49bde 2.4 ± 0.14bec 54.9 ± 1.1d%
Group (VII) n= 8 25.5 ± 0.47def 1.5 ± 0.1def 35.8 ± 1.8&f
a Statistically significant compared to the corresponding value in group (I) (p < 0.001).
b Statistically significant compared to the corresponding value in group (II) (p < 0.001).
c Statistically significant compared to the corresponding value in group (III) (p< 0.001).
d Statistically significant compared to the corresponding value in group (IV) (p< 0.001).
e Statistically significant compared to the corresponding value in group (V) (p< 0.001).
f Statistically significant compared to the corresponding value in group (VI) (p< 0.001).
& Statistically significant compared to the corresponding value in group (IV) (p< 0.05).
% Statistically significant compared to the corresponding value in group (III) (p< 0.05).
Figure 2 Effect of EPO and E on TNF-a (pg /mg) and MPO (u/gm) levels in renal tissue of all groups. (A and B) Comparison between
mean ± SD of TNF-a (PG/mg) and MPO (u/gm) levels in renal tissue of group (I): control group, group II: (RIR group), group III:
(RIR + EPO group), group IV: (OVR+ RIR group), group V: (OVR+ RIR + E group), group VI: (OVR + RIR + EPO group) and
group (VII): (OVR + RIR + E + EPO). a = statistically significant compared to the corresponding value in group (I) (p< 0.001).
b = statistically significant compared to the corresponding value in group (II) (p< 0.001). c = statistically significant compared to the
corresponding value in group (III) (p< 0.001). d = statistically significant compared to the corresponding value in group (IV)
(p< 0.001). e = statistically significant compared to the corresponding value in group (V) (p< 0.001).
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icant decrease in RBF with decrease in NO and increase in
ET1 when compared with the control group. These results
can be explained by many studies29,30, and31 which reported
that RIR causes direct endothelial damage with abnormal vas-
cular tone due to increased sensitivity to vasoconstrictors and
decreased vasodilatation in arterioles. Endothelial injury also
causes cell swelling and narrowing of the vascular lumen, fur-
ther reducing blood flow. Reperfusion paradoxically causes
further impairment of flow. Increased solute delivery to the
distal nephron, in part due to tubular epithelial injury,
enhances vasoconstriction by activating tubuloglomerular
feedback mechanisms. The resulting basal tone and persistent
vasoconstriction contribute to decrease in RBF. Also Golig-
orsky et al.32 proposed the key role of endothelial dysfunction
in acute renal ischemia, suggesting that the defective produc-
tion of endothelial NO may eventually lead to the destruction
of tubular epithelial cells through vascular congestion. Inaddition Müller et al.33 reported that RIR enhanced ET-1 pro-
duction in renal tissues and explained that there is accumulat-
ing evidence indicating that ET-1 plays an important role in
the pathogenesis of ischemic ARF.
This study showed that RIR in non-ovariectomized rats led
to significant decrease in renal level of EPO when compared
with the control group. This finding is in accordance with Plot-
nikov et al.34 who revealed that Ischemia followed by reperfu-
sion is a common pathological trigger for the kidney damage
considering the high vulnerability of this organ to the transi-
tions, which occur during cessation and restoration of blood
flow leads to mitochondrial fragmentation, so decreasing the
synthesis of EPO.
Concerning the inflammatory mechanism as a pathophysi-
ology of RIR injury the current study showed that RIR caused
significant increase in TNF-a and significant increase in MPO
as a marker of neutrophil infiltration when compared with
control group. These results coincide with those of Nasser
Figure 3 Effect of EPO and E on scoring of renal tissue damage
of all groups. Comparison between mean ± SD of scoring of renal
tissue damage of group (I): control group, group II: (RIR group),
group III: (RIR + EPO group), group IV: (OVR + RIR group),
group V: (OVR + RIR + E group), group VI: (OVR + RIR +
EPO group) and group (VII): (OVR + RIR + E+ EPO).
a = statistically significant compared to the corresponding value
in group (I) (p< 0.001). b = statistically significant compared to
the corresponding value in group (II) (p< 0.001). c = statistically
significant compared to the corresponding value in group (III)
(p< 0.001). d = statistically significant compared to the corre-
sponding value in group (IV) (p< 0.001). # = statistically signif-
icant compared to the corresponding value in group (V)
(p< 0.005). & = statistically significant compared to the corre-
sponding value in group (V) (p< 0.01). @ = statistically signif-
icant compared to the corresponding value in group (VI)
(p< 0.01).
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increase synthesis of pro-inflammatory cytokine such as
TNF-a. As injury of the endothelium that characterizes RIR
enhanced leukocyte–endothelial cell adhesion with activation
of platelets and the local coagulation pathway. The adherence
of neutrophils to the vascular endothelium is the first step in
the extravasation of these cells into injured tissue. After adher-
ence and chemotaxis, infiltrating neutrophils can release reac-
tive oxygen species that damage the tubular cells.37
In the current study RIR in ovariectomized rats as in OVR+
RIR group leads to significant deterioration of renal function
and RBF with significant increase in renal damage score when
compared with RIR in non-ovariectomized rats indicating the
protective effect of the endogenous estrogen on renal function.
In spite of significant increase in EPO level in ovariectomized
rats there was significant deterioration of renal damage. We
can explain that estrogen deficiency induced by ovariectomy
abolished the protective effect of E on the kidney. These results
were in agreement with the results of Hutchens et al.38 as they
reported that loss of ovarian steroids resulted in enhanced
renal injury after renal ischemia. These results are in line with
Pinheiro and Silva39 who reported that the RIR injury was
exacerbated by ovariectomy. Conversely, Park et al.40 showed
that deprivation of estrogen in female animals by ovariectomy
did not affect ischemic renal injury, as ovariectomy in this
study was carried out 15 days before bilateral renal ischemia
not four weeks before RIR as in this study.
The estrogen effect on renal EPO level was proved in our
study by significant decrease in EPO level in E + RIR+
OVR group when compared with RIR + OVR group. These
results were in agreement with those of Peschle et al.41
who demonstrated increased EPO production in femaleovariectomized and male rats subjected to hypoxic stress and
showed that normal female rats had lower EPO levels after
hypoxia than normal males, or ovariectomized rats.
In the current study we demonstrated that OVR + E +
RIR group showed better histological results and renal blood
flow, compared to those of RIR. That might reflect that dose
of treated E is higher than that of replacement. As we used
in this study E at a dose of 25 lg/kg/day (SC for three weeks),
which is more than the physiological dose used by Peschle
et al.41 who used E benzoate as replacement therapy in OVX
rats at doses 2.5, 5 or10 mcg per day for 5 days.
By studying the effect of estrogen supplementation to
ovariectomized rats exposed to RIR, it resulted in significant
decrease in BUN, serum creatinine and renal damage score
with significant increase in RBF when compared with OVR+
RIR group. We attributed these results to the significant
decrease of ET-1 and significant increase in NO in addition
to its anti-inflammatory effect on renal tissue. And so estrogen
caused significant increase in RBF and improved renal damage
and renal function. These results were in line with the results of
Müller et al.42 and Masanori et al.43 who showed that 17b-
oestradiol was capable of preventing the renal dysfunction
and tissue injury induced by RIR in male rats. They also found
that the effects of 17b-oestradiol were accompanied by a
decrease in renal content of ET-1, a deleterious mediator in
the pathogenesis of ischemic ARF. Thus, 17b-oestradiol
appears to suppress the enhanced ET-1 production in renal tis-
sues and the consequent renal damage in this model of ARF.
In this study RIR in female either ovariectomized or leads
to significant increase in ET-1 level in renal tissue indicating its
role in the pathogenesis of RIR injury. These results were in
line with the results of Kuro et al.44 and Masanori et al.43
who showed that endothelin-1 is implicated in renal ischemia.
In addition RIR leads to significant decrease in nitrate level in
renal tissue reflecting decrease in NO. These results were in
agreement with results obtained by Thomas and Tanya45
who found that renal NO generation was significantly lower
in acute kidney injury.
To the best of our knowledge, this is the first report that
analyzes the effect of E on the inflammatory response of
RIR. This study revealed significant decrease in TNF-a and
MPO activity in renal tissue after E administration indicating
its anti-inflammatory effect. This may be due to the effect of E
on increasing NO. NO decreases inflammation and inhibits
adhesion of neutrophils to TNF-a activated endothelial cells.46
Estrogen treatment (pregnancy levels) inhibited burn-induced
elevation in serum TNF a levels and the increase of MPO
activity in liver and lung.47
By studying the effect of EPO supplementation at a dose of
5000 U/kg single dose IP, 20 min before ischemia reperfusion
either in ovariectomized or in non-ovariectomized rats, we
found a significant decrease in BUN, serum creatinine and
renal damage score with significant increase in RBF and renal
EPO level when compared with OVR + RIR group or RIR
group. Our findings are in agreement with, numerous studies
that revealed that administration of EPO protected tissue
and whole-organ function in various experimental settings of
RIR.48–50
In the current study EPO administration either in ovariec-
tomized or in non-ovariectomized rats leads to significant
increase in RBF when compared with OVR + RIR group
and RIR group and this can be explained in the current study
Figure 4 Histological results of all group. (A) A photomicrograph renal sections stained with H & E showed no histopathological
changes in kidney of sham operated group. (B) Kidney sections of RIR group showed severe vacuolization and congestion with
development of severe necrosis in tubular cells. (C) Kidney sections of RIR + EPO group showed moderate tubular cell vacuolization and
necrosis. (D) Kidney sections of RIR + OVR group showed severe vacuolization and congestion with development of severe necrosis in
tubular cells. (E) Kidney sections of RIR + OVR + E group showed mild vacuolization and congestion with mild necrosis in tubular
cells. (F) Kidney sections of RIR + OVR + EPO group showed mild vacuolization and congestion with mild necrosis in tubular cells. (G)
Kidney sections of RIR + OVR + E + EPO group showed moderate vacuolization and congestion with moderate necrosis in tubular
cells (H & E 20).
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MPO levels .These results were in agreement with the results
of Moore and Bellomo51 who revealed that pretreatment with
EPO in cisplatin induced acute renal failure leads to significant
increase in RBF. NO is one of signaling pathways associated
with EPO. It has been reported that EPO stimulates vascular
NO production directly or indirectly through stimulation of
the endothelial NO synthase and increasing shear stress in
endothelial cells.52
EPO administration in ovariectomized rats exposed to
RIR showed significant decrease in RBF when compared
with E administration in ovariectomized rats exposed to
RIR. This may be due to the enhanced ET-1 release by
EPO as shown in this study. These results were in agreement
with those of Carlini et al.53 who found that EPO has a direct
stimulatory effect on ET-1 release through an increase in its
synthesis.
EPO supplementation before ischemia reperfusion either
in ovariectomized or in non-ovariectomized rats resulted in
significant decrease in TNF-a and MPO when compared with
OVR + RIR group or RIR group. These findings are inagreement with, several studies53,54 which have demonstrated
that complement system and inflammatory pathway are acti-
vated by RIR injury. Pro-inflammatory cytokine and chemo-
kine production start to increase in damaged tissue. These
chemokines attract neutrophils and macrophages to the
injured kidney and pretreatment with EPO significantly
decreases polymorphonuclear leukocyte infiltration and tissue
MPO activity. Other study showed that EPO treatment inhi-
bits renal inflammation during RIR damage by decreasing
proinflammatory cytokines, TNF-a, IL-6 and NF- B
activation.55
To the best of our knowledge, this is the first report that
analyzes the effect of combination of estrogen with EPO on
a RIR model. This study revealed significant decrease in the
protective effect of EPO as regards serum creatinine, BUN,
renal damage score when combined with estrogen as in
OVR + RIR+ E + EPO group when compared with the
group that receives EPO only (OVR+ RIR+ EPO group).
This can be explained by significant decrease in serum EPO
level in OVR + RIR+ E + EPO group when compared with
the group that receives EPO only (OVR + RIR+ EPO
Effects of erythropoietin and estrogen on ischemia reperfusion injury 333group). This indicates that E significantly decreases EPO renal
level, so decreasing its renal protective effect. As well as RIR in
ovariectomized rats showed significant increase in EPO when
compared with RIR group and combination of EPO and estro-
gen in EPO + E + RIR+ OVR leads to significant decrease
in EPO when compared with EPO+ RIR+ OVR group.
This means that estrogen deficiency induced by ovariectomy
led to increase in renal EPO level, while Combination of estro-
gen and erythropoietin which is more than the physiological
dose with EPO as in EPO + E + RIR+ OVR leads to signif-
icant decrease in EPO renal level when compared with EPO+
RIR+ OVR group. These results were in agreement with
those of Zahra et al.56 who reported that E decreases hypoxic
induction of plasma EPO, and reduces EPO gene expression in
kidneys.57This can be explained by Mukundan et al.58 who
revealed that 17b-estradiol attenuates EPO expression in part
by interfering with hypoxic increases in both expression and
activity of hypoxia inducible factor-1 a protein (HIF-1a)
which is a heterodimeric transcription factor that is responsible
for activation of many hypoxia-inducible genes including EPO
through an estrogen receptor-dependent mechanism. Also
Mukundan et al.59 reported that 17 b -Estradiol decreased
hypoxic induction of plasma EPO and renal EPO mRNA
expression in OVX rats by increasing NO production. NO
attenuates HIF-1 activity/stability during hypoxia thereby
decreasing expression of hypoxia induced genes.60 Another
mechanism explained by Bishop et al.61, who showed that
17b-estradiol might directly alter intracellular iron and zinc
distribution, affecting the oxygen-sensing system, so sup-
presses Epo gene induction.62
In the current study there was non-significant difference in
the level of TNF-a and MPO activity in OVR + RIR+ E +
EPO group when compared with the group that receives EPO
only (OVR+ RIR+ EPO group). This may be due to the
anti-inflammatory effect of E, that may exceed its ability to
decrease the level of EPO and its anti-inflammatory effect.
Treatment with EPO in EPO+ RIR+ OVR leads to sig-
nificant increase in EPO when compared with RIR + EPO
group. These results go parallel with those of 9 who showed
that women on hemodialysis therapy require a greater dose
of EPO to attain a hematocrit equivalent with men and
because they show a lower level of EPO and higher exogenous
EPO also would be needed to reach the same protective effect
that they found in males. Also they observed that the protec-
tive effect of EPO against RIR injury is sex related and more
pronounced in male than in female rats.5. Conclusion
Endogenous estrogen has some protective effect on renal dam-
age in female rats. In addition treatment with EPO and E
demonstrated a protective role against RIR injury in female
rats; however, combination of both leads to decrease in the
protective effect of EPO alone. So treatment with E should
be decreased or stopped in menopausal female supplemented
with EPO in acute renal injury.
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